ES2606168T3 - Compuestos bencil aralquil éter, método para preparar los mismos, compuestos intermedios, uso de dichos compuestos, procedimiento para el tratamiento y/o prevención, composición farmacéutica y medicamento que contiene la misma - Google Patents

Compuestos bencil aralquil éter, método para preparar los mismos, compuestos intermedios, uso de dichos compuestos, procedimiento para el tratamiento y/o prevención, composición farmacéutica y medicamento que contiene la misma Download PDF

Info

Publication number
ES2606168T3
ES2606168T3 ES10811042.0T ES10811042T ES2606168T3 ES 2606168 T3 ES2606168 T3 ES 2606168T3 ES 10811042 T ES10811042 T ES 10811042T ES 2606168 T3 ES2606168 T3 ES 2606168T3
Authority
ES
Spain
Prior art keywords
compounds
prevention
caused
treatment
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10811042.0T
Other languages
English (en)
Spanish (es)
Inventor
Artur Franz Keppler
Sérgio Luiz SACURAI
Marcio Henrique Zaim
Carlos Eduardo Da Costa Touzarim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolab Sanus Farmaceutica Ltda
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43627099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2606168(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Application granted granted Critical
Publication of ES2606168T3 publication Critical patent/ES2606168T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
    • C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
    • C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
    • C07C22/08—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES10811042.0T 2009-08-28 2010-08-27 Compuestos bencil aralquil éter, método para preparar los mismos, compuestos intermedios, uso de dichos compuestos, procedimiento para el tratamiento y/o prevención, composición farmacéutica y medicamento que contiene la misma Active ES2606168T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR0904249 2009-08-28
BRPI0904249-0A BRPI0904249B1 (pt) 2009-08-28 2009-08-28 Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, uso dos referidos compostos, composição farmacêutica
PCT/BR2010/000276 WO2011022798A1 (pt) 2009-08-28 2010-08-27 Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, compostos intermediários, uso dos referidos compostos, método de tratamento e/ou prevenção, composição farmacêutica e medicamento contendo os mesmos

Publications (1)

Publication Number Publication Date
ES2606168T3 true ES2606168T3 (es) 2017-03-23

Family

ID=43627099

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10811042.0T Active ES2606168T3 (es) 2009-08-28 2010-08-27 Compuestos bencil aralquil éter, método para preparar los mismos, compuestos intermedios, uso de dichos compuestos, procedimiento para el tratamiento y/o prevención, composición farmacéutica y medicamento que contiene la misma

Country Status (24)

Country Link
US (1) US8975289B2 (enExample)
EP (1) EP2471781B1 (enExample)
JP (1) JP5718334B2 (enExample)
KR (1) KR101765752B1 (enExample)
CN (1) CN102625800A (enExample)
AR (1) AR078115A1 (enExample)
AU (1) AU2010286266B2 (enExample)
BR (1) BRPI0904249B1 (enExample)
CA (1) CA2771044C (enExample)
CL (1) CL2012000463A1 (enExample)
DK (1) DK2471781T3 (enExample)
ES (1) ES2606168T3 (enExample)
HU (1) HUE032199T2 (enExample)
IL (1) IL218044A (enExample)
IN (1) IN2012DN00611A (enExample)
MX (1) MX2012002276A (enExample)
PE (1) PE20120921A1 (enExample)
PL (1) PL2471781T3 (enExample)
PT (1) PT2471781T (enExample)
RU (1) RU2548009C2 (enExample)
SG (1) SG178298A1 (enExample)
UA (1) UA108479C2 (enExample)
WO (1) WO2011022798A1 (enExample)
ZA (1) ZA201201442B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579829B (zh) * 2012-03-06 2013-09-18 康莉 一种治疗牛放线菌病的中药组合物及其制备方法
CN104016837B (zh) * 2014-05-26 2016-08-24 武汉有机实业有限公司 4,4’-二甲基二苄基醚的制备方法
RU2603622C1 (ru) * 2015-06-25 2016-11-27 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Комплексный метод лечения тейлериоза мелкого рогатого скота
CN108047147A (zh) * 2017-12-08 2018-05-18 长江大学 一类三唑类化合物以及作为杀菌剂的用途
KR101983575B1 (ko) * 2017-12-21 2019-06-03 대한민국 신균주 세라토바시디움 속 js1289 및 이의 용도
CN114222573A (zh) * 2019-08-16 2022-03-22 普度研究基金会 蛋白酶体核心颗粒的小分子刺激物
JP2023057423A (ja) * 2021-10-11 2023-04-21 国立大学法人 熊本大学 ムコール症治療薬
CN117945867B (zh) * 2024-01-12 2026-06-12 海南师范大学 一种抗菌活性苄基苯醚类衍生物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
DE2333354C2 (de) * 1973-06-30 1983-12-15 Bayer Ag, 5090 Leverkusen 2-Aryloxy-2-(imidazol-1-yl)-äthanole sowie deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide
GB1475271A (en) 1975-04-30 1977-06-01 Pfizer Ltd 1-aryl-2-1-imidazolyl-alkyl ethers and thioethers and their use as antifungal agents
DE2556319A1 (de) * 1975-12-13 1977-06-23 Basf Ag Substituierte triazol-aether
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4277475A (en) * 1979-01-11 1981-07-07 Syntex (U.S.A.) Inc. Contraceptive methods employing 1-substituted imidazole derivatives
BE885957A (nl) 1980-10-31 1981-04-30 Amylum Graanderivaten Raff Inrichting voor de continue bereiding van zetmeellijm
US4368186A (en) * 1981-05-07 1983-01-11 Syntex (U.S.A.) Inc. Methods and compositions for intravaginal contraception
DE3314738A1 (de) * 1983-04-23 1984-10-25 Bayer Ag, 5090 Leverkusen Azolylethyl-benzyl-ether-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
JP2875140B2 (ja) * 1993-08-16 1999-03-24 明治製菓株式会社 抗ｍｒｓａ組成物
US5461068A (en) 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
WO2006081327A2 (en) * 2005-01-25 2006-08-03 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
GB0714226D0 (en) * 2007-07-20 2007-08-29 Therapeutics Ltd E anti-bacterial combination therapy
GB0724996D0 (en) * 2007-12-21 2008-01-30 Therapeutics Ltd E Antibacterial combination therapy for the treatment of gram positive bacterial infections
GB0813211D0 (en) * 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
CA2735460A1 (en) * 2008-08-29 2010-03-04 The Uab Research Foundation Novel anti-arrhythmia agent

Also Published As

Publication number Publication date
PT2471781T (pt) 2016-12-15
PL2471781T3 (pl) 2017-08-31
AU2010286266B2 (en) 2015-02-12
AR078115A1 (es) 2011-10-12
HUE032199T2 (en) 2017-08-28
AU2010286266A1 (en) 2012-04-05
KR20120050490A (ko) 2012-05-18
RU2012110925A (ru) 2013-10-10
DK2471781T3 (da) 2017-01-02
EP2471781A1 (en) 2012-07-04
KR101765752B1 (ko) 2017-08-07
IN2012DN00611A (enExample) 2015-06-12
EP2471781B1 (en) 2016-09-07
JP5718334B2 (ja) 2015-05-13
US8975289B2 (en) 2015-03-10
IL218044A0 (en) 2012-04-30
CL2012000463A1 (es) 2012-09-21
US20120196908A1 (en) 2012-08-02
CA2771044A1 (en) 2011-03-03
IL218044A (en) 2017-02-28
BRPI0904249B1 (pt) 2018-03-06
SG178298A1 (en) 2012-03-29
UA108479C2 (en) 2015-05-12
EP2471781A4 (en) 2013-01-23
MX2012002276A (es) 2012-04-19
ZA201201442B (en) 2012-10-31
CA2771044C (en) 2017-07-04
CN102625800A (zh) 2012-08-01
RU2548009C2 (ru) 2015-04-10
WO2011022798A1 (pt) 2011-03-03
BRPI0904249A2 (pt) 2011-05-17
PE20120921A1 (es) 2012-08-01
JP2013503111A (ja) 2013-01-31

Similar Documents

Publication Publication Date Title
Scher et al. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis
AU2006339841B2 (en) Pharmaceutical composition for external use
CN1791378A (zh) 抗真菌指甲/趾甲涂剂及使用方法
WO2009053741A3 (en) Novel formulation
AU2016207029A1 (en) Compositions and methods for inhibiting fungal infections
Ghannoum et al. Evaluation of antifungal efficacy in an optimized animal model of Trichophyton mentagrophytes-dermatophytosis
RU2013110003A (ru) Комбинация соединений для лечения или предотвращения кожных заболеваний
Osborne et al. Antifungal drug response in an in vitro model of dermatophyte nail infection
Al‐Hatmi et al. Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole
US10172811B2 (en) Topical antifungal composition for treating onychomycosis
HUE032199T2 (en) Benzylalkyl ether compounds, a process for their preparation, intermediates, the use of these compounds, a method of treatment and / or prophylaxis, pharmaceutical compositions containing them and medicaments
Chandana et al. Comparison of safety and efficacy of laliconazole and other antifungal agents
RU2417073C2 (ru) Противогрибковая композиция
Ayanlowo et al. Onychomycosis: updates and management challenges A Review
Täuber et al. In vitro evaluation of the antifungal efficacy of poloxamer 407-based formulations in an infected nail plate model
Tamimi et al. Treatment strategies for controlling antifungal resistance in Candida onychomycosis
RU2013120455A (ru) Комбинированный препарат для лечения грибковых заболеваний ногтей
EP2910245A1 (en) Topical antifungal composition for treating onychomycosis
Belikov et al. INFLUENCE OF WAVELENGTH OF LIGHT ON ANTIMYCOTIC ACTIVITY OF CHLORINECONTAINING PHOTODYNAMIC DRUGS
US8119696B2 (en) Treatment of superficial and cutaneous mycoses with a pure form of 1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione
Chakraborty et al. Current developments in prevention and treatment of candidiasis: A review
Roberts et al. Causal agents, clinical presentation and management of fungal skin and nail infections
Ahmedova et al. Identification of sensitivity of dermatomycosis agents towards antimycotics
Shemer et al. Fungal Infections (Onychomycosis
UA136622U (uk) Антимікробний препарат